American Association of Nurse Anesthetists

Board of Directors

President -- Patricia R. Fleming, CRNA
Wesley Long Community Hospital, Greensboro, NC

President-Elect -- Patrick M. Downey, CRNA
Holy Family Hospital, Manitowoc, WI

Vice President -- Barbara V. Adams, CRNA
Baptist Hospital of Miami, Miami, FL

Treasurer -- Richard G. Ouellette, CRNA, MEd
Addison Gilbert Hospital, Gloucester, MA

Director, Region 1 -- Kathleen M. Vainosky, CRNA, BS
Albany Medical Center Hospital School for Nurse Anesthetists, Albany, NY

Director, Region 2 -- Peggy L. McFadden, CRNA, BS
Veterans Administration Hospital, Lexington, KY

Director, Region 3 -- James J. Claffey, CRNA, BS
Wayne State University School of Nurse Anesthetists, Detroit, MI

Director, Region 4 -- Gerald Messbarger, CRNA, BS
Good Samaritan Hospital, Kearney, NE

Director, Region 5 -- Maureen M. Poulos, CRNA, BS
Monticello Medical Center, Longview, WA

Director, Region 6 -- Joseph C. Kovalich, CRNA, MEd
Sacred Heart Hospital Center, Allentown, PA

Director, Region 7 -- Elaine M. Klein, CRNA, MA
The Children's Hospital, Birmingham, AL

Executive Office Staff
Park Ridge, IL

Education Director
John F. Garde, CRNA, MS

Continuing Education Director
Susan Smith Caulk, CRNA, MA

Executive Secretary to Councils on Accreditation and Certification
Mary M. Cavagnaro, CRNA, MA

Membership Director
Josephine H. Heimler, CRNA

Public Relations Director/Editor
Betty Prochaska Colitti, BS

Controller
Dennis C. Kane, CPA, MBA

Legislative/Employment Practices Coordinator
John E. Kasper, BBA, APS

Editorial Staff

Managing Editor, Betty Prochaska Colitti; CRNA Editorial Consultant, Josephine H. Heimler, CRNA; Assistant Editor, Denise M. Dungan; Publications Secretary, Laura Crumback.

Editorial Advisory Board

Margot Barrett, CRNA, Chicago, IL; Kathleen M. Dole, CRNA, BS, Birmingham, AL; MAJ Cecil B. Drain, CRNA, MS, ANC, Fort Sam Houston, TX; Fred O. Foster, CRNA, MA, Honolulu, HI; Vera D. Griner, CRNA, BS, Cincinnati, OH; COL Sarah A. Halliburton, CRNA, PhD, ANC, New Braunfels, TX; Celestine M. Hartigan, CRNA, MS, Detroit, MI; Linda C. Larson, CRNA, MS, Los Angeles, CA; Esther L. Reece, CRNA, MS, Villa Hills, KY; Barbara Reep, CRNA, BA, Decatur, GA; LCR Charles A. Reese, CRNA, PhD, USN, Portsmouth, VA; Sandra S. Shreve, CRNA, Erie, PA; Suzanne F. Stoltzner, CRNA, BSN, Rock Springs, WY; Sandra D. Tunajek, CRNA, Louisville, KY; Thomas B. Wooley, CRNA, MA, Birmingham, AL.

Journal Faculty

Nancy J. Wittstock, CRNA, MS, Detroit, MI; Kathleen M. Dole, CRNA, BS, Birmingham, AL; Sandra M. Maree, CRNA, BS, Winston-Salem, NC; Esther L. Reece, CRNA, MS, Villa Hills, KY; Barry Powell, CRNA, MN, Whitmore Lake, Mi; Helen F. Vos, BSN, CRNA, ret., Winston-Salem, NC; Linda C. Larson, CRNA, MS, Los Angeles, CA; MAJ Cecil B. Drain, CRNA, MS, ANC, Fort Sam Houston, TX; Sandy Frye-Kryder, CRNA, MS, Los Angeles, CA; Leah E. Katz, CRNA, EdD, Los Angeles, CA; Joe R. Williams, CRNA, MS, Dothan, AL; Nancy H. Bruton, CRNA, BS, Winston-Salem, NC; Christine S. Zambricki, CRNA, MS, Detroit, MI; James G. Couriand, CRNA, BS, Groten, CT; LCR Charles A. Reese, CRNA, PhD, USN, Portsmouth, VA.

Contributions

Contributions are invited. Letters from readers will be accepted for publication if they relate to specific articles appearing in the Journal and are signed. The editor reserves the right to edit letters to suit legal and space requirements. For manuscript information, see index.

Business address

Send all editorial copy and classified advertising correspondence to the AANA Journal, 216 Higgins Road, Park Ridge, IL 60068. Send subscriptions in care of subscription department.

Change of address

Please allow six weeks notice of change of address by sending old address clipped from AANA Journal envelope along with new address and zip code to Subscription Department, AANA Journal, 216 Higgins Road, Park Ridge, IL 60068.

Subscription rates

The rate to nonmembers is $24.00 for the 1983 calendar year or $5.00 per issue. Subscriptions are sold only for the calendar year.

Advertising

Send display advertising, correspondence, insertion orders, printing materials to Thomas A. Kenney, Sales Manager, AANA Journal, No. Woodbury Road/Box 56, Pitman, New Jersey 08001. Questions or general information may be directed to Sales Representatives—Anthony J. Iannetti, Inc.—(609) 589-2319; Midwest Office (312) 644-0834.

The opinions expressed in the Journal are those of the contributors and do not necessarily reflect the views of the American Association of Nurse Anesthetists, the AANA Journal or the editorial staff.

The AANA Journal, an official publication of the American Association of Nurse Anesthetists, is published bimonthly as a source of original information for persons interested in the art and science of anesthesia and the role and functions of the nurse anesthetist. Second-class postage paid in Park Ridge, Illinois; additional mailing office. Reproduction up to 250 words is allowed if the Journal is credited but longer quotation requires written approval from the author and publisher. Copyright 1983 American Association of Nurse Anesthetists, 216 Higgins Road, Park Ridge, Illinois 60068. (312) 692-7050. Material subject to this copyright appearing in the Journal may be photocopied for the noncommercial purpose of scientific or educational advancement.
A traditional cushion...

with a clear advantage:

Single use

- soft air-filled cushion contours to a wide variety of faces to provide the most effective seal ever.
- seal will reduce high levels of waste gases in OR breathing zone.
- the added benefit of clarity to aid in recognition of regurgitation or aspiration.
- ideal for OB anesthesia and resuscitation.

Yes, I would like a sample of Vital Signs face mask. Please call collect 201-471-1424 or return this card to Vital Signs, Inc., 1 Madison St., E. Rutherford, N.J. 07073

NAME __________________________
HOSPITAL _______________________
ADDRESS _________________________
CITY ___________ STATE _____ ZIP _______
ANTILIRIUM CONTAINS A TERTIARY AMINE AND EASILY PENETRATES THE BLOOD BRAIN BARRIER, WHILE AN ANTICHOLIN-ESTERASE, SUCH AS NEOSTIGMINE, WHICH HAS A QUATERNARY AMMONIUM ION IS NOT CAPABLE OF CROSSING THE BARRIER. ANTILIRIUM CAN REVERSE BOTH CENTRAL AND PERIPHERAL ANTICHOLINERGIA.

INDICATIONS: To reverse the effects, toxic or otherwise, upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. It also has been reported that ANTILIRIUM (physostigmine) may antagonize the CNS-depressant effects of diazepam.

Dramatic reversal of the effects of the anticholinergic symptoms can be expected in minutes after the intravenous administration of ANTILIRIUM, if the diagnosis is correct and the patient has not suffered anoxia or other insult.

CONTRAINDICATIONS: ANTILIRIUM should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestines or urogenital tract or any vagotonic state, and in patients receiving choline esters or depolarizing neuromuscular blocking agents (decamethonium, succinylcholine).

WARNING: If excessive symptoms of salivation, emesis, urination and defecation occur, the use of ANTILIRIUM should be terminated. If excessive sweating or nausea occur, the dosage should be reduced.

Intravenous administration should be at a slow, controlled rate, no more than 1 mg per minute. Rapid administration can cause bradycardia, hypersalivation leading to respiratory difficulties and possibly convulsions.

An overdosage of ANTILIRIUM can cause a cholinergic crisis.

PRECAUTIONS: Because of the possibility of hypersensitivity in an occasional patient, atropine sulfate injection should always be at hand since it is an antagonist and antidote for physostigmine.

ADMINISTRATION AND DOSAGE: The usual dose of ANTILIRIUM is 0.5 to 2.0 mg intramuscularly or intravenously. Intravenous administration should be at a slow, controlled rate of no more than 1 mg per minute. It may be necessary to repeat dosages of 1 mg to 4 mg at intervals as life threatening signs such as arrhythmias, convulsions and deep coma recur. Physostigmine salicylate is rapidly metabolized (60 to 120 minutes) in the body.

PEDIATRIC DOSAGE: Should be reserved for life threatening situations only. Initially no more than 0.5 mg by very slow intravenous injection of at least one minute duration. If the toxic effects persist, and there is no sign of cholinergic effects, the dose may be repeated at 5 to 10 minute intervals until a therapeutic effect is obtained or a maximum dose of 2 mg is attained.

IN ALL CASES OF POISONING, THE USUAL SUPPORTIVE MEASURES SHOULD BE UNDERTAKEN.

HOW SUPPLIED: Ampuls, 2 ml. packed 12 per box, 1 mg per ml.

CAUTION: Federal law prohibits dispensing without prescription.

REFERENCES:

O'Neal, Jones & Feldman Pharmaceuticals
5510 Metro Boulevard • St. Louis, Missouri 63143
Our team can make a critical difference with your team.

The VSM*1 vital signs monitor and the LIFEPAK* family of defibrillator/monitors may have different functions, but have a common name in quality: Physio-Control.

Like the LIFEPAK family from Physio-Control, the VSM1 vital signs monitor is simple to operate, easy to read and offers convenient service from the best team in the industry. Features that can make the difference to the success of a patient care team.

Manufacturers of the LIFEPAK family of defibrillator/monitors.

Redmond, Washington USA · (206) 881-4000
©1983 Physio-Control Corporation

Please send information on the VSM*1 vital signs monitor from Physio-Control.

Mail to:
Physio-Control Corporation
11811 Willows Road
Redmond, Washington 98052-1013 USA
Attn: Communications Department

<table>
<thead>
<tr>
<th>Name</th>
<th>Facility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zip</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
More than 25,000,000 doses
28,300,000 to date

HOSPITAL-PROVEN

Stadol® IM IV
(butorphanol tartrate)

BRISTOL®
Bristol Laboratories
Division of Bristol-Myers Company
Syracuse, New York 13201

Copyright © 1962, Bristol Laboratories